Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Regeneron agrees to spend up to $213M to acquire Decibel Therapeutics 

By Brian Buntz | August 14, 2023

Regeneron logoTo date, 2023 is shaping up to be a relatively brisk year for M&A deals. A recent case in point is Regeneron’s acquisition of Decibel Therapeutics. The centerpiece of the deal is DB-OTO, a gene therapy intended for patients with otoferlin-related hearing loss. The drug is in its first clinical trial. Regeneron agreed to pay $4.00 per share for Decibel stock with the potential to pay up to $3.50 per share in cash if Decibel hits agreed-upon regulatory milestones for DB-OTO in a specified time frame, bringing the total value of the deal to roughly $213 million.

Last year, Decibel touted DB-OTO’s ability to support otoferlin expression for several weeks before it plateaued. The company said the data for the drug were in line with earlier preclinical research in which mice achieved a functional recovery.

Involved in transmission of sound signals in the inner ear, the protein otoferlin is essential for hearing. Deficiency or mutations in the gene that produces otoferlin can cause hearing impairment. Preclinical research reveals the protein is involved in synapse maturation in inner and outer hair cells. 

Back story on the Regeneron acquisition of Decibel Therapeutics

Regeneron has a history of working with Decibel Therapeutics. The companies have worked together on three gene therapy programs, along with the preclinical programs AAV.103 and AAV.104, which target various forms of congenital, monogenic hearing loss.

Relatively few companies have specialized in drug development for hearing and balance disorders. Two such companies, Frequency Therapeutics and Otonomy, have struggled recently. In February 2021, Frequency Therapeutics hit a stock valuation of just over $55 per share. It was recently trading at $0.68. The company is also a lawsuit magnet. As for Otonomy, in late 2022, it said it planned to dissolve its business and liquidate its assets after its drug Otividex missed its primary endpoint in Ménière’s disease. 

While companies like Frequency Therapeutics and Otonomy have faced clinical trial setbacks in hearing loss, broader interest in neuro-otology and medical devices for ear disorders remains strong. Regeneron’s acquisition of Decibel Therapeutics brings additional resources to the therapeutic area. 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

This image shows the logos of GE HealthCare and Nihon Medi-Physics.
GE HealthCare to fully own Nihon Medi-Physics
This is the logo of Johnson & Johnson.
Johnson & Johnson brings in billions from remaining Kenvue stake
bruker logo
Bruker to acquire NanoString business
Vertex Pharmaceuticals to acquire Alpine Immune Sciences in $4.9B deal
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE